Alyftrek 50 mg/20 mg/4 mg film-coated tablets and 125 mg/50 mg/10 mg film-coated tablets
*Company:
Vertex Pharmaceuticals (Ireland) LimitedStatus:
UpdatedLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 19 December 2025
File name
ema-combined-h-6382-en-IRL_SPC.pdf
Reasons for updating
- Change to section 6.3 - Shelf life
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 01 December 2025
File name
ema-combined-h-6382-en-IRL_PIL.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
Updated on 01 December 2025
File name
ema-combined-h-6382-en-IRL.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 09 July 2025
File name
Alyftrek Tablets PIL-Initial MAA.pdf
Reasons for updating
- New PIL for new product
Updated on 09 July 2025
File name
Alyftrek Tablets SmPC-Initial MAA.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Vertex Pharmaceuticals (Ireland) Limited
 Limited.webp)
Address:
Vertex Pharmaceuticals (Ireland) Limited, Unit 49, Block 5, Northwood Court, Northwood Crescent, Dublin 9, D09 T665, IrelandMedical Information E-mail:
vertexmedicalinfo@vrtx.comTelephone:
+353 (1) 7617299Fax:
+44 (0)20 3204 5220Medical Information Facsimile:
+44 (0)1235 438 190Medical Information Direct Line:
1800 924568Customer Care direct line:
1800924568